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Summary
Background:  Xuefu  Zhuyu  Capsule  (XFZY)  has  been  commonly  used  for  relieving  chest  pain  in
patients with  coronary  heart  disease  (CHD).  Randomized  controlled  trials  (RCTs)  on  XFZY  in
treating unstable  angina  (UA)  have  not  been  systematically  reviewed.disease); Objective:  This  study  aims  to  provide  a  PRISMA-compliant  systematic  review  to  evaluate  the
efﬁcacy of  XFZY  in  treating  UA.Bu  Wen  Ding  Xin  jiao
tong  (unstable  angina
pectoris)
Methods:  An  extensive  search  of  7  medical  databases  was  performed  up  to  June  2013.  RCTs
involving XFZY  or  combined  with  conventional  drugs  versus  conventional  drugs  were  identiﬁed.
Meta-analysis  was  performed  to  evaluate  the  cardiovascular  effects  of  XFZY.  Rev  Man  5.0  was
used for  data  analysis.
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392  
Results:  8  RCTs  were  included  
XFZY combined  with  conventional
1.26 [1.16,  1.38];  P  <  0.00001)  and
conventional  drugs  alone.  No  seve
Conclusions:  XFZY  combined  wit
effects in  treatment  of  UA  with  
are still  needed.
© 2014  Published  by  Elsevier  Ltd.
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ntroduction
ngina  pectoris,  a  symptom  of  coronary  heart  disease
CHD),  manifests  as  stress-induced  ischemic  episodes  result-
ng  in  severe  chest  pain.1 When  the  same  symptoms
ccur  at  rest  or  become  severe,  unstable  angina  (UA)  is
he  diagnosis.2 UA  is  an  acute  coronary  syndrome  and
hould  be  treated  as  an  emergency.  It  can  increase  risk
f  acute  myocardial  infarction  (heart  attack)  and  severe
ardiac  arrhythmias  which  leading  to  sudden  death.3 There-
ore,  treatment  should  begin  as  soon  as  possible  after
and  low-molecular-weight  heparin.4,5 Therapeutic  aims  are
to  improve  quality  of  life  by  decreasing  anginal  attacks  and
to  prevent  myocardial  infarction  and  death.  But  not  all  of
these  drugs  are  useful  in  every  form  of  UA,  and  treatment
is  symptomatic  rather  than  curative.6 The  other  drawbacks
of  current  anginal  medications  are  adverse  effects  and  drug
resistance.7 Treatment  of  UA  with  good  prognosis  remains  a
challenging  clinical  issue.
Chinese  herbal  medicine  (CHM)  has  a 3000-year-old  his-
tory  with  unique  theories  for  concepts  of  etiology  and
systems  of  diagnosis  and  treatment.8 Recently,  there  isnset  of  unstable  angina.  The  ACC/AHA  guidelines  support
nti-ischemic  therapy,  antiplatelet  therapy  and  antithrom-
otic  therapy.  Anti-ischemia  therapies  include  nitroglycerin,
eta  blocker,  and  oxygen  as  required.  Antiplatelet  thera-
ies  include  aspirin,  clopidogrel,  and  platelet  glycoprotein
Ib/IIIa  inhibitor.  Antithrombotic  therapies  include  heparin
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in  this  review.  Statistical  analysis  of  the  results  showed  that
 drugs  had  signiﬁcant  effect  on  relieving  angina  symptoms  (RR:
 improving  ECG  (RR:  1.20  [1.04,  1.38];  P  =  0.01)  compared  with
re  adverse  events  were  reported.
h  conventional  drugs  appears  to  have  potential  cardiovascular
few  adverse  events.  However,  further  rigorous  designed  trials
 growing  and  sustained  interest  in  the  beneﬁts  of  CHM
nd  potential  drug  interactions  with  western  medications,
specially  for  patients  with  UA.9,10 CHM  has  been  used
or  activating  the  blood  and  resolving  stasis  in  clini-
al  practice  for  the  treatment  of  UA  in  China.  Xuefu
huyu  Tang,  a  famous  formula  for  treating  Xueyu  (blood
ent
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sChinese  patent  medicine  Xuefu  Zhuyu  capsule  for  the  treatm
stagnation),  consists  of  rehmannia  root  (shengdi),  peach
seed  (taoren),  Safﬂower  (honghua),  Chinese  angelica  (dang-
gui),  red  peony  root  (chishao),  platycodon  root  (jiegeng),
orange  fruit  (zhiqiao),  hare’s  ear  root  (chaihu),  Sichuan
lovage  root  (chuanxiong), two-toothed  achyranthes  root
(niuxi),  and  prepared  liquorice  root  (gancao).  Xuefu  Zhuyu
Tang  has  been  made  into  various  high  standard  pharma-
ceutical  preparations  such  as  capsule,  pill,  tablet,  granule
and  oral  liquid.  For  instance,  Xuefu  Zhuyu  Capsule  (Hong
Ren  Tang  Pharmaceutical  Co.,  Ltd.,  Tianjin,  China)  consists
of  rehmannia  root  (shengdi)  43.24  mg,  peach  seed  (taoren)
43.24  mg,  Safﬂower  (honghua)  43.24  mg,  Chinese  angelica
(danggui)  43.24  mg,  red  peony  root  (chishao)  43.24  mg,
platycodon  root  (jiegeng)  32.44  mg,  orange  fruit  (zhiqiao)
32.44  mg,  hare’s  ear  root  (chaihu) 32.44  mg,  Sichuan  lovage
root  (chuanxiong) 43.24  mg,  two-toothed  achyranthes  root
(niuxi)  21.62  mg,  prepared  liquorice  root  (gancao)  21.62  mg.
The  total  dose  is  2.4  g  for  one  day.  Experimental  studies  have
shown  that  XFZY  can  increase  coronary  blood  ﬂow,  improve
the  cardiac  microcirculation,  prevent  platelet  aggregation,
and  accommodate  blood  lipids.11,12
Several  studies  published  in  China  have  reported  that
XFZY  can  enhance  the  effect  of  relieving  of  angina  symp-
toms,  decreasing  the  dosage  of  nitroglycerin  and  lessening
side  effects  for  patients  with  UA.13—16 Liu  et  al.14 had
undertaken  meta-analysis  of  Chinese  patent  medicine  Xuefu
Zhuyu  capsule  for  the  treatment  of  angina  pectoris,  which
include  stable  and  unstable  angina  pectoris  trials  together.
However,  the  evidence  supporting  or  disproving  its  cardio-
vascular  effects  is  not  robust.  Our  review  presents  a  more
vigorous  attempt  to  examine  the  efﬁcacy  and  safety  of  XFZY
for  patients  with  UA.
Methods
Search  strategy
Two  authors  (X.  Yang  and  G.  Yang)  searched  the  follow-
ing  electronic  databases:  PubMed,  the  Cochrane  Center
Controlled  Trials  Register  (2013),  EMBASE  (1980—2013),
Chinese  Biomedical  Literature  Database  (CBM,  1978—June
2013),  Chinese  National  Knowledge  Infrastructure  (CNKI,
1979—June  2013),  Chinese  Scientiﬁc  Journal  Database  (VIP,
1989—June  2013),  and  Wanfang  Med  Online  Database
(WMOD,  1998—June  2013).  The  searching  terms  were
‘‘Xuefu  Zhuyu’’,  ‘‘Guan  xin  bing  (coronary  heart  disease)’’,
and  ‘‘Bu  Wen  Ding  Xin  jiao  tong  (unable  angina  pectoris)’’.
No  language  restriction  was  applied.
Types  of  studies
Randomized  controlled  trials  that  evaluate  the  cardiovascu-
lar  effects  of  XFZY  for  UA  were  included.  Quasi-RCTs  were
not  considered.
Types  of  participantsThe  participants  who  suffering  from  and  being  treated
for  angina  pectoris  were  included,  regardless  of  the  dis-
ease  and  severity.  Diagnosis  of  UA  was  according  to  ‘‘the
c
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002  ACCF/AHA  Guideline  for  the  Diagnosis  and  Manage-
ent  of  Patients  with  Unstable  Ischemic  Heart  Disease  (2002
CCF/AHA)’’  or  ‘‘the  International  Society  and  Federation
f  Cardiology/World  Health  Organization  (ISFC/WHO)’’.17,18
e  did  not  intend  to  make  any  restrictions  on  age,  gender,
nd  race.
ypes  of  interventions
he  medicine  of  treatment  group  was  XFZY  combined  with
onventional  drugs  for  patients  with  UA  regardless  of  man-
factures,  preparation  form,  dose  and  duration.  The  study
as  designed  to  compare  the  effectiveness  and  safety  of
FZY  used  only  or  in  combination  with  conventional  drugs
ersus  conventional  drugs  alone  or  plus  placebo.
ypes  of  outcome  measures
he  primary  outcome  measures  were  mortality  due  to
schemic  heart  disease  and  the  incidence  of  a heart  event
e.g.  AMI,  severity  arrhythmia,  heart  failure,  revasculariza-
ion).  The  secondary  outcome  measures  were:  (1)  reduction
f  angina  symptoms  (e.g.  Effective  symptomatic  improve-
ents  should  achieve  at  least  50%  or  80%  reduction  in
requency  of  feeling  angina  chest  pain).18 (2)  ECG  improve-
ent  (e.g.  Effective  ECG  improvements  should  achieve  at
east  0.05  mV  lowering  at  ST  segment  in  ECG  or  nearly  nor-
al  ECG  during  an  exercise  test),18 and  (3)  quality  of  life.19
he  adverse  events  were  also  measured.
tudy  selection
he  titles  and  abstracts  of  potentially  relevant  references
ere  identiﬁed  through  the  literature  search  and  reviewed
ndependently  by  2  reviewers  (X.  Yang,  and  X.  Xiong)  accord-
ng  to  predeﬁned  criteria.  Discrepancies  regarding  whether
o  include  or  exclude  a  study  were  resolved  by  consensus
ith  other  investigator  (J.  Wang).
ata  extraction
he  following  data  were  extracted:  (1)  citations  (authors  of
tudy,  year  of  publication),  (2)  methodological  information,
3)  participants  (sample  size,  age),  (4)  detailed  informa-
ion  of  interventions  and  controls,  (5)  outcome  measures,
nd  (6)  adverse  events.  Two  reviewers  (X.  Xiong,  X.  Yang)
hecked  the  disagreement  of  data  extraction.  Differences
n  data  extraction  were  resolved  by  discussion.
rial  quality  assessment
wo  authors  (Y.  Zhang,  G.  Yang)  independently  assessed
he  methodological  quality  of  included  RCTs  using  Cochrane
isk  of  bias  tool.  The  qualities  of  included  RCTs  were
ssessed  according  to  seven  speciﬁc  domains:  (1)  random
equence  generation  (selection  bias),  (2)  allocation  con-
ealment  (selection  bias),  (3)  blinding  of  participants  and
ersonnel  (performance  bias),  (4)  blinding  of  outcome  data
attrition  bias),  (5)  incomplete  outcome  data  (attrition
ias),  (6)  selective  reporting  (reporting  bias),  and  (7)  other
394  X.  Yang  et  al.
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ias.  When  completing  each  of  the  seven  domains  for  a
tudy,  information  was  provided  according  to  RevMan  5.0:
1)  a  description  of  included  study;  and  (2)  their  judgment
n  the  risk  of  bias  as  a  consequence  of  this.  This  judgment
s  categorized  by  using  one  of  the  three  answers:  ‘high  risk’,
unclear  risk’  and  ‘low  risk’.
tatistical  analysis
eta-analysis  was  performed  if  the  intervention,  control,
nd  outcome  were  the  same  or  similar.  According  to  RevMan
.0  provided  by  Cochrane  Collaboration,  dichotomous  data
ere  expressed  as  risk  ratio  (RR)  and  continuous  outcomes  as
eighted  mean  difference  (WMD),  with  their  95%  conﬁdence
ntervals  (CI)  respectively.  The  statistical  heterogeneity  was
xamined  with  the  I2-test,  where  I2 values  of  50%  or  more
ere  considered  to  be  indicators  of  a  substantial  level  of
eterogeneity.  In  the  absence  of  signiﬁcant  heterogeneity
I2 <  50%),  we  pooled  data  using  a  ﬁxed-effect  model,  other-
ise  we  using  random  effects  model  (I2 >  50%).20
esult
iterature  search  and  study  selectionur  initial  searches  ﬁnally  identiﬁed  610  articles  accord-
ng  to  the  search  strategy,  among  which  252  studies  were
xcluded  because  of  duplicated  publication.  After  checking
t
m
a
ty  search  and  selection.
he  abstracts,  405  articles  were  excluded  because  of  non-
linical  studies,  with  obvious  error,  or  with  study  objectives
ifferent  from  the  aim  of  this  review,  etc  (Fig.  1).  Full  texts
f  53  articles  were  retrieved  for  further  identiﬁcation,  and
nally  8  RCTs21—28 were  included  according  to  the  inclusion
riteria.  The  included  RCTs  were  all  conducted  in  China  and
ublished  in  Chinese.
haracteristics  of  the  trials  included
he  characteristics  of  included  RCTs  were  summarized  in
able  1. The  number  of  participants  ranged  from  28  to
0,  with  a  total  of  534  patients  (265  patients  in  treat-
ent  groups)  in  the  8  studies.  The  age  of  the  participants
anged  from  35  years  to  82  years.  The  studies  included  only
nterventions  with  XFZY  plus  conventional  drugs  versus  con-
entional  drugs  alone  or  plus  placebo.  Because  no  RCTs  of
FZY  versus  conventional  drugs  alone  or  plus  placebo  was
ounded.  Conventional  drugs  referred  to  treatment  accord-
ng  to  the  guidelines  for  UA,  including  platelet  aggregation
nhibitor  (aspirin),  nitrates,  beta-blockers,  calcium  channel
lockers,  and  ACE  inhibitors.  The  total  treatment  duration
anged  from  1  weeks  to  8  weeks.  Reductions  in  angina  symp-
oms  and  improvement  in  ECG  were  the  most  commonly
easured  outcomes  in  the  included  studies.  None  trial
dopted  mortality  as  primary  outcome.  1  trial26 reported
he  quality  of  life  of  UA  patients.
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Table  1  The  characteristics  of  included  RCTs  of  XFZY  for  UA.
Study  ID Sample  (T/C) Diagnosis
standard
Age  Intervention  group Control  group Course
(week)
Outcome  measures
21Qiu  and  Yang  2012  [21] 30/30  1979  40—78 XFZY  +  conventional
drugs
Conventional  drugs 2  RAS
ISFC/WHO
22Zhang  and  Song  2006  [22] 50/50  2002  35—79 XFZY  Conventional  drugs 3  RAS,  ECG
ACCF/AHA +Conventional
drugs
23Wang  2011  [23] 40/40  2002  60.3  ±  8.3 XFZY  Conventional  drugs 4  RAS,  adverse  event
ACCF/AHA +Conventional
drugs
24Zhao  et  al.  [24] 30/31  1979  46—65  XFZY  Conventional  drugs  1  RAS
ISFC/WHO +Conventional
drugs
25Li  et  al.,  2008  [25] 30/30  2002  50—70 XFZY  +  isosorbide Isosorbide  dinitrate,
aspirin
4  RAS,  ECG
ACCF/AHA Dinitrate,  aspirin
26Chu  et  al  2009  [26] 28/29  2002  50—70 XFZY  Conventional  drugs 4  RAS,  life  quality
ACCF/AHA +Conventional
drugs
+placebo  of  XFZY
27Wang  and  Lou  2009  [27] 28/28  1979  Not  clear XFZY  conventional  drugs 2  RAS,  ECG,
ISFC/WHO +Conventional
drugs
28Zheng  and  Wang  2009  [28] 30/30  1979  40—82 XFZY  Conventional  drugs 8  RAS,  ECG
ISFC/WHO +Conventional
drugs
Notes: XFZY: Xuefu Zhuyu Capsule; RAS: reduction of angina symptoms.
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Table  2  Analyses  of  reduction  of  angina  symptoms.
Trials  Intervention
(n/N)
Control
(n/N)
RR  [95%  CI]  P  Value
XFZY  plus  conventional  drugs  versus  conventional  drugs  1  26/30  19/30  1.37  [1.01,  1.86]  0.04
XFZY plus  conventional  drugs  versus  conventional  drugs  1  47/50  41/50  1.15  [0.99,  1.33]  0.07
XFZY plus  conventional  drugs  versus  conventional  drugs  1  37/40  30/40  1.23  [1.01,  1.51]  0.04
XFZY plus  conventional  drugs  versus  conventional  drugs  1  28/30  21/31  1.38  [1.06,  1.79]  0.02
XFZY plus  isosorbide  dinitrate  and  aspirin  versus
isosorbide  dinitrate  and  aspirin
1  28/30  24/30  1.17  [0.95,  1.43]  0.14
XFZY plus  conventional  drugs  versus  conventional  drugs 1  25/28  18/28  1.39  [1.02,  1.88]  0.03
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AXFZY plus  conventional  drugs  versus  conventional  drugs
ethodological  quality  of  included  trials
ll  of  these  studies  indicated  randomization  with  a  single-
enter,  parallel-design,  but  most  of  them  did  not  describe  it
learly.  2  trials26,28 reported  that  the  random  sequence  was
enerated  by  a  random  digits  table.  None  of  trials  describe
llocation  concealment  and  methods  of  assessing  compli-
nce.  1  trial26 mentioned  that  they  were  single  blind  of
ubjects,  but  included  no  descriptions  of  the  procedures.  1
rial26 reported  drop-out  or  withdraw,  but  none  of  trials  had
 pre-trial  estimation  of  sample  size,  which  indicated  the
ack  of  statistical  power  to  ensure  appropriate  estimation
f  the  therapeutic  effect.
rimary  outcomes
one  trial  adopted  mortality  as  primary  outcome.  There  was
o  report  of  ischemic  heart  disease  and  the  incidence  of  a
eart  event  (e.g.  AMI,  severity  arrhythmia,  heart  failure,
evascularization).
eduction  of  angina  symptoms  (RAS)
 total  of  7  trials21—25,27,28 with  477  patients  used  reduc-
ion  of  angina  symptoms  (RAS)  to  measure  the  outcome.
t  is  showed  homogeneity  in  the  results  (P  =  0.74,  I2 =  0%).
hus,  we  did  a  quantitative  data  synthesis  (meta-analysis)  by
xed-effects  model.  The  outcome  shows  a  statistically  sig-
iﬁcant  difference  in  favor  of  the  combination  group  of  XFZY
nd  conventional  drugs  (RR:  1.26  [1.16,  1.38];  P  < 0.00001).
t  is  suggested  that  XFZY  plus  conventional  drugs  had  a bet-
er  effect  on  relieving  symptoms  of  angina  (Table  2).
F
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Table  3  Analyses  of  improvement  of  ECG.
Trials  
XFZY  plus  conventional  drugs  versus  conventional  drugs  1  
XFZY plus  isosorbide  dinitrate  and  aspirin  versus
isosorbide  dinitrate  and  aspirin
1  
XFZY plus  conventional  drugs  versus  conventional  drugs 1  
XFZY plus  conventional  drugs  versus  conventional  drugs 1  28/30  21/30  1.33  [1.04,  1.72] 0.03
CG  improvement
 total  of  4  trials22,25,27,28 with  276  patients  used  ECG  to  mea-
ure  the  outcome.  It  is  showed  homogeneity  in  the  results
P  =  1.2400,  I2 =  0%).  Thus,  we  did  a  quantitative  data  syn-
hesis  (meta-analysis)  by  ﬁxed-effects  model.  The  outcome
hows  a  statistically  signiﬁcant  difference  in  favor  of  the
ombination  group  of  XFZY  and  conventional  drugs  (RR:  1.20
1.04,  1.38];  P  =  0.01).  It  is  suggested  that  XFZY  plus  conven-
ional  drugs  had  a  better  effect  on  improving  ECG  (Table  3).
mprovement  of  life  quality
wo  trials26,28 reported  the  improvement  of  life  quality  of
atients  after  4—8  weeks  of  treatment  with  XFZY  combined
ith  conventional  drugs.  The  statistical  data  show  that  XFZY
lus  conventional  drugs  was  better  than  conventional  drugs
lone  with  regard  to  relieving  body  symptoms  (MD:  8.03
1.12,  14.96])  and  promoting  anginal  stability  (MD:  12.13
4.61,  19.65]).
ublication  bias
ue  to  no  sufﬁcient  number  of  trials,  we  failed  to  perform
unnel  plot  to  detect  publication  bias.
dverse  effective  trials23,28 reported  adverse  effects  relating  to  the
reatment  by  XFZY  combined  with  conventional  drugs.  The
dverse  effects  included  headache  and  nausea.  The  approx-
mate  rates  of  these  adverse  effects  were  2%  (6/265)  and
Intervention
(n/N)
Control
(n/N)
RR  [95%  CI]  P  Value
36/50  30/50  1.20  [0.90,  1.60]  0.21
27/30  23/30  1.17  [0.93,  1.48]  0.17
24/28  20/28  1.20  [0.91,  1.59]  0.20
23/30  19/30  1.21  [0.86,  1.69]  0.27
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1.5%  (4/265)  respectively.  No  severe  adverse  events  were
reported.
Discussion
This  systematic  review  included  8  randomized  trials  and
a  total  of  534  participants.  The  main  ﬁndings  of  this  sys-
tematic  review  were  that  XFZY  combined  with  conventional
drugs  demonstrated  potential  effect  on  relieving  symptoms
of  angina  (RR:  1.26  [1.16,  1.38];  P  <  0.00001)  and  improving
ECG  (RR:  1.20  [1.04,  1.38];  P  =  0.01)  compared  to  conven-
tional  drugs  alone.  XFZY  as  an  adjunctive  treatment  to
conventional  drugs  has  good  effects  on  treating  patients
with  UA.  However,  the  evidence  remains  weak  due  to  the
low-quality  of  the  trials.  Thus,  available  data  are  not  ade-
quate  to  draw  a  deﬁnite  conclusion  of  combination  therapy
for  UA.  And  the  positive  ﬁndings  should  be  interpreted  con-
servatively  due  to  the  following  facts.
Firstly,  the  quality  of  the  included  RCTs  was  generally
low.  (1)  Randomization:  all  the  included  trials  claimed  ran-
domization;  however,  2  trials  provided  sufﬁcient  information
on  randomization.26,28 The  other  trials  mentioned  random-
ization  but  without  further  details,  which  did  not  allow  a
proper  judgment  of  the  conduct  of  the  trials.  It  could  lead
to  selection  bias.  (2)  Blinding:  only  1  trial26 mentioned  that
they  were  single  blind  of  subjects,  but  included  no  descrip-
tions  of  the  procedures.  The  rest  studies  were  lack  of  any
blinding  method,  either  blinding  of  participants  and  per-
sonnel  or  blinding  of  outcome  assessment.  It  could  directly
lead  to  performance  bias  due  to  patients  and  researchers
being  aware  of  the  therapeutic  interventions  for  the  sub-
jective  outcome  measures.  (3)  Sample  size:  none  of  trials
had  a  pre  trial  estimation  of  sample  size,  which  indicated
the  lack  of  statistical  power  to  ensure  appropriate  estima-
tion  of  the  therapeutic  effect.  And  all  of  the  included  trials
were  of  single  center.  Sample  size  calculation  should  be  con-
ducted  before  enrollment.  (4)  Placebo  controlled:  1  trial26
had  placebo  control,  which  use  ‘‘A  +  B  versus  B  +  placebo
of  A’’;  however,  the  rest  included  trials  used  ‘‘A  +  B  versus
B’’  design  which  patients  were  randomized  to  receive  XFZY
plus  conventional  drugs  treatment  versus  conventional  drugs
control  treatment  without  a  rigorous  control  for  placebo
effect.  Consequently,  positive  conclusions  would  be  draw
due  to  nonspeciﬁc  placebo  effects.  (5)  Analysis  of  data:
only  1  trial26 had  reported  the  dropouts,  but  without  the
intention-to-treat  analysis.  Therefore,  the  positive  ﬁndings
should  be  interpreted  conservatively.  It  could  lead  to  attri-
tion  bias.  Nevertheless,  there  were  2  trials25,26 conducted  by
3—7  authors.  The  rest  6  trials  were  only  conducted  by  one
or  two  authors.  It  is  difﬁcult  to  accomplish  an  RCT  which
including  randomization,  allocation  concealment,  blinding
and  analysis  by  less  than  3  doctors.  It  could  also  lead  to
performance  bias.29—32
Secondly,  all  the  included  trials  used  reduction  of  angina
symptoms  or  ECG  test  as  the  main  outcomes.  There  were
only  a  few  trials  report  the  original  data  about  the  frequency
and  duration  of  chest  pain  or  reduction  of  nitroglycerin  dose,
however  it  was  indicated  a  substantial  level  of  heterogeneity
of  these  data,  and  meta-analysis  did  not  be  adopt.  All  the
RCTs  claimed  that  the  positive  effect  of  XFZY  combined  with
conventional  drugs  is  better  than  conventional  drugs  alone. of  unstable  angina  pectoris  397
egative  ﬁndings  almost  have  not  been  reported.  We  tried
o  conduct  extensive  searches  for  unpublished  material,  but
o  unpublished  ‘‘negative’’  studies  were  found,  which  could
ead  to  publication  bias.
Thirdly,  patients  in  UA  should  be  treated  carefully
ecause  the  risk  of  acute  MI  and  severe  cardiac  arrhythmias
ay  increase  and  lead  to  sudden  death.  Indeed,  none  of  the
ncluded  trials  reported  the  mortality  rate  or  the  incidence
f  complications.  It  is  likely  to  require  longer  periods  of
reatment  due  to  the  duration  of  included  trials  only  ranged
rom  1  to  8  weeks.  Moreover,  the  severity  of  angina  symp-
oms  may  exacerbate  without  reasonable  treatment,  thus
 longer  follow-up  period  with  serial  measurements  of  out-
omes  is  suggested  to  determine  the  long-term  efﬁcacy  of
hinese  patent  medicine.33—35
Fourthly,  the  safety  problem  of  integrative  medicine
herapy  with  both  conventional  western  medicine  and
radition  medicine  is  generally  concerned.36,37 Herb-drug
nteraction  is  an  important  focus  of  this  systematic  review.
here  were  2  trials  reported  the  adverse  effect  of  XFZY
n  combination  with  conventional  drugs.  The  main  adverse
ffects  included  headache  (6/265)  and  nausea  (4/265).
onsidering  that  limited  report  of  adverse  events,  conclu-
ions  on  the  safety  of  XFZY  could  not  be  drawn.
Generally,  as  the  quality  of  8  trials  reviewed  and  included
n  meta-analysis  were  generally  weak,  further  high  quality
rials  are  needed  to  assess  the  effectiveness  of  XFZY  com-
ined  with  conventional  drugs  in  treating  UA.  To  improve
he  trial  design  quality,  future  researchers  should  follow
he  basic  guidelines  for  reporting  clinical  trials  such  as  the
ONSORT  statement,  and  treatment  process  should  be  mon-
tored  rigorously  and  reported  appropriately  in  the  future
linical  trials.38—42
onclusion
ur  systematic  review  suggest  that  XFZY  in  combination
ith  conventional  drugs  may  have  good  effect  on  reducing
ngina  symptoms  and  improving  ECG  with  few  side  effects
or  patients  with  UA.  However,  the  deﬁnite  conclusion  can-
ot  be  drawn  due  to  the  low  quality  of  included  trials.  More
igorously  designed,  large-sample,  randomize  controlled  tri-
ls  should  be  performed  in  the  future.
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